

# Yun Cai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/807727/publications.pdf>

Version: 2024-02-01

58  
papers

1,697  
citations

393982

19  
h-index

288905

40  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtle relationships between <i>Pseudomonas aeruginosa</i> and fungi in patients with cystic fibrosis. <i>Acta Clinica Belgica</i> , 2022, 77, 425-435.	0.5	7
2	Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis. <i>International Urogynecology Journal</i> , 2022, 33, 1103-1123.	0.7	6
3	Model-Informed Precision Dosing of Antibiotics in Osteoarticular Infections. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 99-110.	1.1	1
4	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	0.8	1
5	Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 72-80.	0.9	11
6	Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of voriconazole in human cerebrospinal fluid. <i>Analytical Methods</i> , 2021, 13, 4585-4593.	1.3	1
7	Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1181-1193.	2.0	4
8	Evaluation of the Potential Effect of Iptakalim Hydrochloride on the QT Interval in Single- and Multiple-Ascending-Dose Studies Using Concentration-QTc Analysis. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1231-1241.	0.8	0
9	Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 380-389.	0.9	5
10	Adjunctive clindamycin therapy in invasive $\beta$ -haemolytic streptococcal infections. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 762.	4.6	0
11	Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of <i>A. baumannii</i> Study. <i>Frontiers in Microbiology</i> , 2021, 12, 678165.	1.5	9
12	Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia. <i>Aging</i> , 2021, 13, 15548-15568.	1.4	4
13	Risk Factors and Prognosis of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections in Respiratory Intensive Care Unit: A Retrospective Study. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3297-3305.	1.1	13
14	Non-carbapenem $\beta$ -lactam/ $\beta$ -lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum $\beta$ -lactamase-producing Enterobacteriaceae: a systematic review. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106410.	1.1	11
15	Evaluation of bioequivalence of two flurbiprofen axetil injections: A randomized, open-label, double-cycle, and crossover study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 660-667.	0.9	2
16	Identification of antibiotic pairs with disjoint resistance: innovative progress made but questions remain. <i>Lancet Microbe</i> , The, 2021, 2, e651.	3.4	0
17	Novel Beta-Lactam/Beta-Lactamase Plus Metronidazole vs Carbapenem for Complicated Intra-abdominal Infections: A Meta-analysis of Randomized Controlled Trials. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa591.	0.4	4
18	Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms. <i>Frontiers in Medicine</i> , 2021, 8, 741940.	1.2	19

#	ARTICLE	IF	CITATIONS
19	Resistance to ceftazidime-avibactam and underlying mechanisms. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 18-27.	0.9	137
20	Determination of voriconazole in human plasma by liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring in Chinese patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988701.	0.4	11
21	Imaging of bioluminescent <i>Klebsiella pneumoniae</i> induced pulmonary infection in an immunosuppressed mouse model. <i>Journal of International Medical Research</i> , 2020, 48, 030006052095647.	0.4	8
22	Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2020, 20, 408.	1.3	20
23	Low-Frequency Ultrasound Enhances Bactericidal Activity of Antimicrobial Agents against <i>Klebsiella pneumoniae</i> Biofilm. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	5
24	Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 435-444.	2.0	1
25	Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR <i>Acinetobacter baumannii</i> : a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3423-3431.	1.3	26
26	Immunomodulatory Effects of Colistin on Macrophages in Rats by Activating the p38/MAPK Pathway. <i>Frontiers in Pharmacology</i> , 2019, 10, 729.	1.6	13
27	Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 809-813.	1.1	11
28	Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence. <i>Frontiers in Pharmacology</i> , 2019, 10, 1389.	1.6	9
29	Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2019, 67, 35-45.	1.7	38
30	Safety and efficacy of colistin alone or in combination in adults with <i>Acinetobacter baumannii</i> infection: A systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 383-400.	1.1	26
31	Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 186-190.	0.8	6
32	Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent <i>Pseudomonas aeruginosa</i> intraperitoneal murine infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 456-461.	1.3	17
33	Multiple Low Frequency Ultrasound Enhances Bactericidal Activity of Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> Biofilms. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	10
34	Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> in an In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	12
35	A Review of the Combination Therapy of Low Frequency Ultrasound with Antibiotics. <i>BioMed Research International</i> , 2017, 2017, 1-14.	0.9	33
36	Efficacy of Linezolid and Fosfomycin in Catheter-Related Biofilm Infection Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	30

#	ARTICLE	IF	CITATIONS
37	Low-Frequency Ultrasound Enhances Antimicrobial Activity of Colistin+Vancomycin Combination against Pan-Resistant Biofilm of <i>Acinetobacter baumannii</i> . <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 1968-1975.	0.7	26
38	Tigecycline: Alone or in combination?. <i>Infectious Diseases</i> , 2016, 48, 491-502.	1.4	13
39	<i>In Vitro</i> Activities of Combinations of Rifampin with Other Antimicrobials against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1466-1471.	1.4	26
40	In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Antibiotics</i> , 2015, 68, 551-555.	1.0	29
41	Real-Time Monitoring of Catheter-Related Biofilm Infection in Mice. <i>Journal of Microbiology and Biotechnology</i> , 2015, 25, 1728-1733.	0.9	0
42	Effect of Proton Pump Inhibitors on In Vitro Activity of Tigecycline against Several Common Clinical Pathogens. <i>PLoS ONE</i> , 2014, 9, e86715.	1.1	14
43	Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials. <i>Chinese Medical Journal</i> , 2014, 127, 1118-25.	0.9	2
44	A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2014, 27, 463-7.	0.2	3
45	In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Antibiotics</i> , 2013, 66, 705-708.	1.0	35
46	The emergence of clinical resistance to tigecycline. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 110-116.	1.1	152
47	Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 309-315.	1.9	10
48	Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial. <i>Journal of Antibiotics</i> , 2012, 65, 175-178.	1.0	10
49	Single-dose pharmacokinetics and safety of iptakalim hydrochloride in Chinese healthy volunteers. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 337-343.	1.2	4
50	Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy. <i>Current Therapeutic Research</i> , 2012, 73, 195-206.	0.5	41
51	Colistin resistance of <i>Acinetobacter baumannii</i> : clinical reports, mechanisms and antimicrobial strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1607-1615.	1.3	476
52	Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 968-978.	1.3	60
53	Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1162-1172.	1.4	170
54	Effects of iron depletion on antimicrobial activities against planktonic and biofilm <i>Pseudomonas aeruginosa</i> . <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1257-1262.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Iron-depletion prevents biofilm formation in <i>Pseudomonas aeruginosa</i> through twitching motility and quorum sensing. <i>Brazilian Journal of Microbiology</i> , 2010, 41, 37-41.	0.8	26
56	<i>In Vitro</i> Antimicrobial Activity and Mutant Prevention Concentration of Colistin against <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3998-3999.	1.4	30
57	Synergistic effects of aminoglycosides and fosfomycin on <i>Pseudomonas aeruginosa</i> in vitro and biofilm infections in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 563-566.	1.3	51
58	Effects of iron depletion on antimicrobial activities against planktonic and biofilm <i>Pseudomonas aeruginosa</i> . <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 1257-1262.	1.2	3